

Small Molecule Targeted Therapy Market Set to Reach \$110.52 Billion by 2029

The Business Research Company's Small Molecule Targeted Therapy Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, October 14, 2025

/EINPresswire.com/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

The Business
Research Company

Small Molecule Targeted Therapy Global Market
Report 2025

What Is The Expected Cagr For The [Small Molecule Targeted Therapy Market](#) Through 2025?

In recent years, there has been significant expansion in the market size of small molecule targeted therapy. It's anticipated to increase from \$70.45 billion in 2024 to \$77.29 billion in 2025, with a compound annual growth rate (CAGR) of 9.7%. The development during the historical span can be traced back to the greater availability of cutting-edge diagnostic tools, the proliferation of clinical trials, a heightened concern for oncology and rare disease treatments, an upswing in regulatory endorsements for innovative small molecule drugs, and a growing interest in combination therapies.

“

"Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors"

*The Business Research
Company*

The market size for small molecule targeted therapies is

predicted to exhibit robust growth in the coming years, estimated to reach \$110.52 billion in 2029 with a compound annual growth rate (CAGR) of 9.4%. This growth during the forecast period can be credited to factors such as incremental prevalence of chronic and genetic diseases, the increasing use of personalized medicine, escalated investments in pharmaceutical R&D, growing cognizance among healthcare professionals and patients, and enhanced governmental support and funding. The forecast period will also see predominant trends like advancements in drug design technology, progress in high-throughput screening methodologies, evolution of precision medicine platforms, enhancements in drug delivery systems driven by technology, and the amalgamation of genomic and proteomic data.

Download a free sample of the small molecule targeted therapy market report:
<https://www.thebusinessresearchcompany.com/sample.aspx?id=28332&type=smp>

What Are The Key Factors Driving Growth In The Small Molecule Targeted Therapy Market?

The expansion of the small molecule targeted therapy market is anticipated to be fuelled by the increasing focus on personalized medicine. This form of healthcare customizes prevention, diagnosis, and treatment based on an individual's genetic, environmental, and lifestyle characteristics. The growth in personalized medicine is spearheaded by advancements in genomics, which provide more profound insights into individual genetic variations, allowing more accurate and targeted treatments. These treatments enhance patient results and abate trial-and-error in therapies. Small molecule targeted therapy bolsters personalized medicine by specifically focusing on a patient's unique molecular or genetic disease makeup, thereby enhancing treatment effectiveness and decreasing adverse effects. For example, the Personalized Medicine Coalition, a non-profit organization based in the United States, reported in February 2024 that the FDA approved 16 new personalized treatments in 2023 for patients with rare diseases, an increase from just six approvals in 2022. The FDA's approvals in 2023 also included seven new drugs for cancer and three for other diseases and conditions. Thus, the rising emphasis on personalized medicine is fuelling the expansion of the small molecule targeted therapy market.

What Are The Top Players Operating In The Small Molecule Targeted Therapy Market?

Major players in the Small Molecule Targeted Therapy Global Market Report 2025 include:

- F. Hoffmann-La Roche AG (Roche)
- Merck KGaA
- Pfizer Inc.
- Bayer AG
- Sanofi S.A.
- Novartis International AG
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc (GSK)
- Eli Lilly and Company

What Are The Key Trends And Market Opportunities In The Small Molecule Targeted Therapy Sector?

Major firms working within the small molecule targeted therapy market are concentrating their efforts on creating innovative solutions such as oral small molecules. These aim to augment targeted delivery, boost patient adherence, and deal with specific molecular tracks in oncology and other chronic diseases. Generally, an oral small molecule is a low molecular mass drug that can be taken orally and engineered to penetrate cells with ease to specifically target proteins or pathways associated with disease. For example, in June 2025, Kura Oncology Inc., a biotech company based in the US, got an FDA nod for a New Drug Application (NDA) for ziftomenib. This

was intended as a therapy for adult patients afflicted with recurring or resistant acute myeloid leukemia (AML) possessing nucleophosmin 1 (NPM1) mutations. Designed as an oral targeted therapy for adults with recurring or resistant AML carrying NPM1 mutations, it meets a pressing unmet medical necessity. It boasts an appealing safety profile and has shown encouraging effectiveness, including substantial rates of complete remission during clinical trials. By selectively impeding the menin-KMT2A interaction, ziftomenib hampers the growth of leukemia cells and encourages new treatment alternatives for this challenging AML subtype.

Comprehensive Segment-Wise Insights Into The Small Molecule Targeted Therapy Market

The small molecule targeted therapy market covered in this report is segmented as

- 1) By Type Of Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
- 2) By Drug Class: Monoclonal Antibodies, Small Molecule Inhibitors, Combination Therapies
- 3) By Mechanism Of Action: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (Ahr) Modulators, Cell Cycle Inhibitors
- 4) By Disease Indication: Cancer, Autoimmune Diseases, Infectious Diseases
- 5) By Route Of Administration: Oral, Intravenous, Subcutaneous

Subsegments:

- 1) By Chemotherapy: Alkylating Agents, Antimetabolites, Anti-microtubule Agents
- 2) By Targeted Therapy: Kinase Inhibitors, Proteasome Inhibitors, Aromatic Hydrocarbon Receptor (AhR) Modulators
- 3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

View the full small molecule targeted therapy market report:

<https://www.thebusinessresearchcompany.com/report/small-molecule-targeted-therapy-global-market-report>

[Global Small Molecule Targeted Therapy Market](#) - Regional Insights

In 2024, North America held the largest share in the global market for small molecule targeted therapy. The fastest growth rate over the forecast period, however, is expected in the Asia Pacific region. The report on small molecule targeted therapy encompasses various global regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Small Molecule Targeted Therapy Market 2025, By [The Business Research Company](#)

Small Molecule Drug Discovery Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report>

Targeted Therapy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report>

Rna Targeting Small Molecules Therapeutics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/857790088>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.